Re: Death Invasion Survival مهكرة
Katerine Aldrige
Death Invasion Survival مهكرة هي لعبة حركية مثيرة حيث تجري أحداث من شخص ثالث. سيجد اللاعب نفسه في مدينة يصاب فيها كثيرون بفيروس يحول الناس إلى زومبي. يبدأ الأشخاص المصابون بالعدوى في السعي لتدمير كل ما يعترض طريقهم بعد تحميل لعبة death invasion survival مهكرة.
لقد حدث أن اثنين من الشخصيات الرئيسية كانا في مركز هذه الأحداث في death invasion survival مهكرة. إنهم لا يحتاجون فقط إلى محاولة البقاء على قيد الحياة في مثل هذه الظروف الصعبة ولكن أيضًا لوقف انتشار المرض. إذا فشلوا فسيكون الكوكب بأكمله في خطر. طريقة اللعب في لعبة death invasion survival مهكرة مثيرة للغاية وستكون قادرة على إثارة اهتمام المستخدم لفترة طويلة.
تدور أحداث لعبة Death Invasion Survival مهكرة للاندرويد عن عالم مهجور حيث تفشى فيروس رهيب لم يقتل الناس فحسب بل حولهم إلى زومبي حقيقيين كان الدافع الوحيد وراءهم هو التعطش للجوع. وسيحتاج اللاعبون إلى لعب دور الجندي الشجاع الذي وقع في مهمة جادة والتي ستحتاج إلى إكمالها بسرعة.
بعد تنزيل لعبة Death Invasion Survival مهكرة سيختار المستخدمون إحدى الشخصيات المتاحة لهم ليبدأوا من أجلها مغامرتهم الخطيرة والممتعة. ستحتاج إلى تسليح نفسك جيدًا لأن الكثير من الأسلحة والذخيرة هو مفتاح النجاح في هذا الموقف. ستحتاج حقًا إلى كمية هائلة من الذخيرة لأن هناك عددًا لا يحصى من القتلى في المدن وسيتعين عليك إنفاق الذخيرة على الجميع حتى تقتلهم جميعًا.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Reactive oxygen species (ROS) are natural by-products of aerobic metabolism and they can promote normal cell proliferation through the activation of growth-related signaling pathways.8 Most anticancer drugs kill their target cells, at least in part, through the generation of elevated amounts of intracellular ROS.9 ROS can exert different effects according to the basal metabolic rate of the cell. The high basal metabolic rate of cancer cells makes them more susceptible to redox-directed therapeutics in comparison with non-transformed cells.10 Redox-directed therapeutics have been developed to act as direct inhibitors of cancer and to sensitize tumors to first-line agents; however, they are associated with significant toxicity.9 The discovery of non-toxic molecules that selectively upregulate ROS in malignant cells would be beneficial.
Cannabidiol (CBD) is a non-toxic and non-psychoactive cannabinoid that has been shown to have antitumor activity in multiple cancer types.11 Activation of CB1 and CB2 receptors has been previously shown to lead to the inhibition of tumor progression;12 however, CBD does not interact efficiently with CB1 and CB2 receptors, and the initial site CBD interacts with to produce antitumor activity is unknown. Our recent study demonstrated CBD-produced robust antitumor activity against a human-derived GBM in an intracranial xenograft model;13 however, no investigations to date have interrogated the therapeutic effects of CBD on GSCs.
One of the major systems used by both normal and cancerous cells to counteract oxidative insult is the NRF2 (also known as NFE2L2) transcriptionally regulated program.9 The role of NRF2 transcriptional regulator and SLC7A11 (solute carrier family 7 (anionic amino-acid transporter light chain), member 11) in mediating GBM response and resistance to redox-directed therapeutics has not been evaluated.
In the current study, we systematically interrogated therapeutic response to CBD using several GSC lines in culture and in vivo. Our results demonstrate that while CBD exhibits significant antitumor activity, a subset of GSCs adapt by activating an extended antioxidant cellular response. We show that cotargeting GSCs using ROS modulators (CBD) and inhibitors of the antioxidant response genes together is more effective than either approach alone in halting GBM growth.
We next performed efficacy studies in vivo, using two models of intracranial GBM xenografts, established by a low number (5 103) of GSC lines 3832 and 387. As demonstrated in Figure 2, this low number of cells can seed highly aggressive tumors. Tumor progression is rapid and the median survival in 3832 and 387 cells was 27 and 21 days, respectively. CBD treatment significantly prolonged survival in tumor bearing mice (Figures 2a and b). Immunohistochemical (IHC) analyses of GBM xenograft tissues demonstrated that CBD treatment inhibited p-AKT, Ki67 and stimulated the activation of caspase-3 in GBM in vivo (Figure 2c). Control antibody and hematoxylin and eosin staining are shown in Supplementary Figure 2. Using bioluminescence measurements, we monitored tumor growth and response to CBD therapy in real time. Our data demonstrate that following initial inhibition of tumor growth by CBD (day 22), intracranial GBM tumors appear to resume a more rapid growth rate in spite of continuous CBD administration (Figure 2d). These data suggest that in vivo, a sub-population of CBD-treated GSCs adapted during therapy and became resistant. We next set out to investigate mechanisms underlying both response and resistance to CBD treatment in tumors derived from GSCs.
To investigate the mechanism underlying the resistant GBM phenotype suggested by partial therapeutic response (Figures 2c and d), we profiled RNA extracted from three GSC lines treated with vehicle and CBD on Affymetrix Gene St 1 DNA Arrays (Affymetrix, Inc., Santa Clara, CA, USA) (Figure 4a). Raw data is available at =GSE57978.
Using standard analyses of microarray in conjunction with Altanalyze software (developed by Dr. Nathan Salomonis; ), we determined that significantly altered transcripts belong to several functional classes. Specifically, we measured a downregulation of stemness markers (MELK, OLIG2), PN markers (DLL3, PDGFRA) and proliferation markers (Ki67, Top2A) (Figure 4a). Concomitantly, we measured significant upregulation of several antioxidant response gene products (SLC7A11, NRF2) as well as MES GBM markers (CD44, TNSFR10, CEBPB; Figure 4a). Taqman validation for a subset of 12 genes was performed using additional GSC lines, as well as acutely dissociated patient GBM cells treated with CBD. Taqman analysis confirmed the molecular signature shift induced by CBD (Figure 4b). Western blot analysis further corroborated these findings in both 3832 and 387 GSC lines (Supplementary Figure 1). Taken together, these data suggest that the partial therapeutic efficacy of CBD against GBM is due to a subset of tumor cells upregulating antioxidant response genes and undergoing an adaptive reprogramming toward a resistant, MES phenotype. PMT has been previously documented to occur in GBM following radiation5or antiangiogenic therapy.17 Given the significant upregulation of the antioxidant response gene products, we investigated whether the phenotypic shift toward a resistant, MES molecular profile was ROS-dependent. Cotreatment with ROS scavenger VitE partially reverted the CBD-induced MES shift measured in 3832 GSCs both at the transcript and protein levels (Figures 4c and d). In agreement with these data, upregulation of the MES marker CD44 was measured specifically in GBM xenografts from CBD-treated mice, in vivo (Figure 4e).
Given the robust upregulation of SLC7A11, we hypothesized that targeting its expression or function would revert some of the adaptive antioxidant response and thus render a more efficient therapeutic response in GSCs. We next used a pool of small interfering RNA (siRNA) sequences to target SLC7A11 in GSC 387, and measured the effects on cell viability and reduced glutathione (GSH) levels. We found that SLC7A11 knockdown inhibited GSH levels and these effects were reverted by pretreatment with the N-acetyl cysteine antioxidant (Supplementary Figures 3a and b). SLC7A11 knockdown cells showed enhanced sensitivity to CBD as compared with control siRNA-treated GSCs (Supplementary Figure 3c). To stably inhibit the expression levels of SLC7A11, we used a lentivirus-mediated knockdown, using two distinct short hairpin RNA (shRNA) sequences. Protein knockdown was significant (Supplementary Figure 3d) and the xCT-knockdown GSCs were impaired in their ability to form tumorspheres (Supplementary Figures 3e and f). Attempts to expand xCT-knockdown cells for in vivo studies were not successful. As previously reported for cell lines,19 pharmacological inhibition of xCT inhibited reduced GSH levels in GSC 3832 (Supplementary Figure 4).
Importantly, CBD in combination with ERA led to a synergistic increase in the inhibition of GSC viability (Figures 7a and b). The effect on viability with the combination of CBD+ERA correlated with an enhanced production of ROS (Figures 7c and d). Furthermore, we performed two functional assays, which measure pathognomonic features of glioma, that is, invasion and self-renewal. Matrigel invasion assays demonstrate that CBD and ERA synergistically inhibited tumor cell invasion, as shown in Figures 7e and f. Self-renewal was assessed using a limited dilution assay, which demonstrated that treatment with CBD+ERA significantly downregulated GBM stem cell frequency in two GSC cell lines (Figures 7g and h). The combination treatment was more efficient than either drug used alone (Figures 7g and h). We have also tested the combination of PE and CBD on GSC 387 viability and our results demonstrate that the two drugs act synergistically to inhibit tumor cell viability (Supplementary Figure 6). Supplementary Table 1 summarizes combination index (CI) values for CBD and various system Xc inhibitors in inhibiting GSC survival, where a CI value of 1 indicates synergistic, additive and antagonistic effects, respectively.
03c5feb9e7